Drug Trial Radar · NCT07684937
HL-300 Ointment in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Jun 14, 2024
Primary completion
Nov 25, 2024
Study completion Nov 25, 2024
Sponsor
- Lead sponsor
- Hangzhou Highlightll Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jul 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate the safety and tolerability of HL-300 ointment following single and multiple topical administrations in healthy Chinese adult volunteers.
Conditions
- Atopic Dermatitis
Interventions
HL-300Drug
Number of Healthy Volunteers:4 (Treatment group: 3, Placebo\*: 1)
HL-300Drug
Number of Healthy Volunteers:8 (Treatment group: 6, Placebo: 2);Dosing Days:Day 1;
HL-300Drug
Number of Healthy Volunteers:12 (Treatment group: 10, Placebo: 2);Dosing Days:Day 1
HL-300Drug
Number of Healthy Volunteers:12 (Treatment group: 10, Placebo: 2);Dosing Days:Day 1-Day 7, BID;
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety and tolerability of HL-300 ointment after single and multiple topical doses in healthy adult volunteers in ChinaTime frame: Single dose: Day3 Day 8;Multiple dose: Day7 Day14
- To evaluate the safety and tolerability of HL-300 ointment after single and multiple topical doses in healthy adult volunteers in ChinaTime frame: Single dose:Day3 Day 8;Multiple dose: Day7 Day14
- To evaluate the safety and tolerability of HL-300 ointment after single and multiple topical doses in healthy adult volunteers in ChinaTime frame: Single dose:Day3, Day 8;Multiple dose: Day3, Day5, Day7, Day9, Day11, Day14
- To evaluate the safety and tolerability of HL-300 ointment after single and multiple topical doses in healthy adult volunteers in ChinaTime frame: Single dose:Day3 Day 8;Multiple dose: Day7 Day14
- To evaluate the safety and tolerability of HL-300 ointment after single and multiple topical doses in healthy adult volunteers in ChinaTime frame: Single-dose: Pre-dose Day1,post-dose Day1-12hour , Day2, Day3, Day8. Multiple-dose: Pre-dose Day1, Day4, Day7,post-dose Day1-12hour , Day7-12hour, Day10, Day14.
- To evaluate the safety and tolerability of HL-300 ointment after single and multiple topical doses in healthy adult volunteers in ChinaTime frame: Single dose: Day 8; Multiple dose: Day7, Day14
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.